Hepatocytes adopt an invasive and metastatic phenotype caused by the cooperation of transforming growth factor (TGF)-b and oncogenic Ha-Ras. In the initial phase of this process, c-Fos is rapidly induced by TGF-b, but then decreases to undetectable levels. Here, we investigated the functional implications of c-Fos activation and its contribution to hepatocellular tumorigenesis. By employing conditional c-Fos expression, we observed that continuous activation of c-Fos and consequently AP-1 activity leads to depolarization of differentiated murine epithelial hepatocytes. Most remarkably, this change in morphology was associated with inhibition of proliferation and induction of cell death. Coexpression of antiapoptotic Bcl-X L or scavenging of reactive oxygen species was sufficient to prevent the c-Fos-mediated phenotype. In contrast, the cooperation of c-Fos with oncogenic Ha-Ras or a Ras mutant selectively activating the MAPK pathway even enhanced c-Fos-induced effects. Showing the negative role in hepatocellular tumorigenesis, c-Fos repressed oncogenic Ras-driven anchorage-independent growth in vitro and strongly suppressed tumour formation in vivo. Taken together, we demonstrate that c-Fos modulates plasticity of epithelial hepatocytes and acts tumour suppressive in neoplastic hepatocytes by stimulating cell cycle inhibition and cell death.
Introduction
The transcription factor c-Fos heterodimerizes with members of the Jun family and forms the activator protein-1 (AP-1) complex, which is crucially involved in a wide range of cellular processes including cell proliferation, transformation and death (Angel and Karin, 1995; Shaulian and Karin, 2002) . Analysis of the negative intervention with c-Fos expression demonstrated its requirement for cell cycle progression and proliferation (Holt et al., 1986; Smith and Prochownik, 1992 ). Yet, fibroblasts lacking c-Fos show an unperturbed cell cycle and exhibit only a partial defect in the cell cycle re-entry after UV exposure (Brusselbach et al., 1995; Schreiber et al., 1995) . With regard to its proto-oncogenic function, c-Fos on its own has the potential to activate malignant transformation of chondroblasts and osteoblasts (Jochum et al., 2001; Shaulian and Karin, 2001 ). This direct involvement of deregulated Fos in oncogenesis has been observed in c-Fos-expressing transgenic mice, developing bone tumours at high frequency, as well as in c-Fos-deficient mice who show inhibition of skin tumorigenesis induced by Ha-Ras plus chemical treatment (Ruther et al., 1987 (Ruther et al., , 1989 Saez et al., 1995) . In contrast to its promoting role in carcinogenesis, c-Fos has also been found to be implicated in apoptosis. Particularly in the nervous system, sustained c-Fos expression precedes and correlates with neuronal cell death (Smeyne et al., 1993) , and c-Fos induction associated with apoptosis has been observed during mammary gland involution and regression of the prostate (Buttyan et al., 1988; Marti et al., 1994) . Similarly, continuous expression of c-Fos after light exposure leads to massive apoptosis of photoreceptors in the retina (Hafezi et al., 1997) . Moreover, stimulation of cell death by exogenous expression of c-Fos has been reported in keratinocytes (Mils et al., 1997) , colon carcinoma cells (Preston et al., 1996) and in pro-B cells with nonfunctional Ag receptor (Hu et al., 1996) .
During compensatory liver regeneration caused by partial hepatectomy (PH) or induced after toxic injury, several transcription factors such as Stat3, NF-kB, c-myc and AP-1 are highly activated (Michalopoulos and DeFrances, 1997; Fausto, 2000) . In particular, AP-1 activity is induced in the immediate early phase of liver repopulation due to the strong transient upregulation of c-Fos and c-Jun in hepatocytes (Columbano and Shinozuka, 1996; Pistoi and Morello, 1996; Taub, 1996) . Studies in gene-targeted animals showed that c-Jun-deficient embryos display defective hepatogenesis by increased apoptotic rates of hepatoblasts (Eferl et al., 1999) , and mice lacking c-Jun in the liver fail to accomplish a compensatory response of hepatocytes after PH (Behrens et al., 2002) . These data clearly demonstrate that c-Jun is not only essential in liver development but also represents a critical regulator of hepatocyte proliferation and survival (Hilberg et al., 1993) . Although the role of c-Jun appears to be wellcharacterized in the liver, the functional implications of c-Fos activation during liver repopulation remain poorly understood. In hepatocarcinogenesis, the consequences of c-Fos expression and the resulting contribution to AP-1 activity are controversially discussed, since recent data revealed a positive regulatory role of cFos at early stages of hepatocellular tumorigenesis (Rahmani et al., 1999) , whereas another report rather showed a promoting function of c-Fos exclusively at late-stage tumour progression (Ito et al., 1998) .
In mammary epithelial cells, the persistent expression of c-Fos is associated with depolarization and the acquisition of an invasive phenotype, a process generally referred to as epithelial to mesenchymal transition (EMT; Reichmann et al., 1992; Thiery, 2002) . The activation of c-Fos mediates the loss of the tumoursuppressive cell adhesion molecule E-cadherin in mammary epithelial cells that is accompanied by a cytoplasmic dispersion and nuclear translocation of the transcription factor b-catenin/LEF, a component of the Wnt signalling pathway (Eger et al., 2000; Stockinger et al., 2001) . In contrast, overexpression of c-Jun in these mammary epithelial cells results in epithelial disorganization without changes in invasive growth (Fialka et al., 1996) . Similar to findings in a mammary EMT model (Oft et al., 1996 (Oft et al., , 1998 Janda et al., 2002) , we recently reported that murine hepatocytes undergo a conversion from a polarized, epithelial morphology to an invasive, metastatic phenotype through the collaboration of TGF-b and active Ha-Ras (Gotzmann et al., 2002) . This process has been considered as an in vitro correlate to hepatocellular late-stage tumorigenesis in vivo, since hepatocytes drastically progress in malignancy by the acquisition of a tissue-infiltrative cellular machinery and by establishing an autocrine loop of TGF-b1 regulation, as frequently observed in human hepatocellular carcinomas (HCCs; Ito et al., 1991; Bedossa et al., 1995; Factor et al., 1997) .
During this hepatocellular EMT, c-Fos expression was observed to be temporally upregulated in the early phase of induction, which was followed by downregulation to undetectable levels. In this report, we analysed the functional role of c-Fos in differentiated murine hepatocytes and in hepatocellular tumorigenesis. We found that continuous c-Fos expression and thus, sustained AP-1 activity, leads to changes in hepatocyte morphology that are associated with a block in proliferation and an increase in cell death. Using multiple genetic and pharmacological approaches, we demonstrate that these c-Fos-mediated effects (i) can be prevented either by scavenging reactive oxygen species (ROS) or by stimulating antiapoptotic signals via Bcl-X L , and (ii) can be strongly enhanced by the collaboration of c-Fos with MAPK signalling. In line with these results, we show that c-Fos expression exhibits a strong negative interference with oncogenic Ras-driven tumorigenesis in vitro and in vivo, indicating that c-Fos is operative as a negative regulator of hepatocarcinogenesis.
Results

c-Fos expression ceases during the early course of hepatocellular EMT
We recently reported the tumour-promoting role of transforming growth factor (TGF)-b in hepatocarcinogenesis showing that TGF-b is operative in inducing and maintaining a transition of epithelial hepatocytes to a spindle-shaped, mesenchymal (fibroblastoid) morphology (EMT) in cooperation with activated Ha-Ras (Gotzmann et al., 2002) . In culture, hepatocellular EMT occurs highly synchronous. Epithelial MMH-R cells, derived from differentiated MMH-D3 hepatocytes by exogenous expression of oncogenic Ha-Ras (Amicone et al., 1997; Gotzmann et al., 2002) , simultaneously undergo EMT after treatment with TGF-b1 (Figure 1a) . At 24 h post-TGF-b1 induction, gross morphological alterations are completed, as visualized by phase contrast microscopy. By analysing a broad array of targets putatively involved in hepatocellular EMT, we observed a rapid upregulation of c-Fos mRNA expression peaking at 0.5-1 h after TGF-b induction, which is strongly diminished after 24 h and ceases to undetectable levels later on (Figure 1b) . In accordance with these data, c-Fos expression levels detected by microarray analyses show a 410-fold decrease 24 h after TGF-b stimulation, which further drop to a 30-fold reduction after completion of EMT (data not shown). This expression pattern of c-Fos during synchronous induction of EMT is similar to the transient upregulation of cFos and its subsequent downregulation at an early stage of liver regeneration (Taub, 1996) . By employing our advanced hepatic cell model, we investigated whether the abolishment of c-Fos expression at an early stage of hepatocellular EMT is a requirement for the progression of hepatocellular tumorigenesis. Hence, we first aimed at determining the phenotypical consequences of continuous c-Fos expression in differentiated hepatocytes, and further analysed the functional implications of sustained c-Fos activation in carcinogenesis.
Phenotypical consequences of continuous c-Fos/AP-1 activation on its own and in cooperation with oncogenic Ha-Ras
To employ conditional gene expression, a bicistron harbouring c-Fos fused to the hormone-binding domain of the estrogen receptor (FosER; Reichmann et al., 1992; Eger et al., 2000) and the green fluorescent protein (GFP) was stably introduced into parental MMH-D3 hepatocytes by retroviral transmission. As shown in Figure 2a , treatment of the resulting MMH-Fos cell line with estradiol (E2) for 48 h led to a Bfourfold increase in the transactivation of an AP-1-dependent luciferase reporter construct. Coexpression of c-Fos and a dominant-negative (dn) version of c-Jun, which is devoid of the N-terminal phosphorylation sites, strongly attenuated c-Fos-mediated transcriptional activity. Thus, the hormonally controlled expression of c-Fos, which was functionally verified by concomitant activity of AP-1, represents a powerful tool to study the effects of continuous c-Fos expression in hepatocytes. MMH-Fos cells induced with E2 for 3 days showed a change in epithelial morphology (Figure 2c, upper panel) , that is, the activation of c-Fos led to a switch of hepatocytes from an epithelial to a rather fibroblastoid phenotype. No morphological changes were observed on parental MMH-D3 after treatment with E2 (data not shown). Although these c-Fos-induced morphological alterations were not associated with a loss or a cytoplasmic dislocation of the cell adhesion molecule Further analyses revealed that continuous c-Fos expression leads to an inhibition of hepatocyte proliferation. As measured by daily cell counts, MMH-Fos induced by E2 exhibited considerably reduced proliferation kinetics, whereas untreated MMH-Fos or E2-treated parental MMH-D3 cells showed an estimated doubling time of about 24 h at exponential growth ( Figure 3a ). This retardation of proliferation was even more pronounced in E2-induced MMH-FosRas cells that display an almost entire growth arrest. In agreement with these data, the analysis of the clonogenic growth behaviour clearly showed that the conditional expression of c-Fos strongly reduces the clonal expansion of MMH-FosRas cells, whereas parental MMH-D3 cells remain unaffected by E2-treatment ( Figure 3b ). In order to discriminate between defects in cell cycle progression and cell death that both contribute to the net balance in cell proliferation, we determined the thymidine incorporation rates after onset of exogenous c-Fos expression. MMH-Fos induced by E2 for 3 days showed a twofold decrease of cells in S phase, which was even more reduced in MMH-FosRas cells (Figure 3c ). These data were corroborated by FACS analysis displaying an accumulation of MMH-Fos and MMHFosRas cells in the G1 phase after induction with E2 (data not shown). Interestingly, these changes in cell cycle distributions were paralleled by a vast increase in cell death, as examined by measuring the release of lactate dehydrogenase (LDH) activity (Figure 3d ). The continuous expression of c-Fos on its own induced cell death effects that were even more pronounced in cooperation with oncogenic Ha-Ras. In agreement with the release of LDH, between 20 and 30% of E2-induced MMH-Fos, and a moderately higher percentage of activated MMH-FosRas cells, showed DNA fragmentation by TUNEL-positive nuclei (Figure 3e ). From these data, we concluded that c-Fos is responsible for the inhibition of hepatocellular proliferation that is accomplished by both its capability to induce cell cycle defects as well as to trigger cell death. Intriguingly, these phenotypical effects of sustained c-Fos expression are indicated to be further enhanced in collaboration with constitutively active Ha-Ras.
c-Fos collaborates with MAPK signalling
To further investigate the cooperation of c-Fos with oncogenic Ha-Ras, we aimed at dissecting the role of Ras by determining the contribution of its downstream effectors. For this, MMH-Fos cells were generated that coexpress an Ras mutant selectively activating either MAPK or PI3 kinase signalling (referred to as MMHFosS35 and MMH-FosC40, respectively, RodriguezViciana et al., 1997). The morphological phenotype of these established cell types was quite remarkable: while MMH-FosC40 cells displayed an epithelial phenotype that exhibited a change in morphology after induction with E2, as described for MMH-Fos cells ( Figure In addition, we found that E2-induced MMH-Fos cells treated with LY294.002, a compound specifically interfering with PKB/Akt activity downstream of PI3 kinase, had no effect on the changes in epithelial morphology induced by c-Fos activation ( Figure 4c , lower left panel). Notably, the morphology resulting from this combined treatment was comparable to MMH-Fos and MMH-FosC40 induced with E2 on its own ( . Thus, these data provide strong evidence that the Ras-hyperactivated PI3 kinase pathway fails to enhance c-Fos effects, whereas the synergy between c-Fos and MAPK is indicated to promote c-Fos-mediated effects.
c-Fos causes ROS production and upregulation of CHOP
We next investigated whether the proapoptotic role of c-Fos is associated with an enhanced production of intracellular ROS that could mediate cell death (Herrera et al., 2001a) . By employing the oxidation-sensitive (Figure 5b ). In addition, the elevated levels of intracellular ROS by continuous c-Fos expression were associated with the upregulation of the stress-dependent transcription factor CHOP (also known as GADD 153). This nuclear protein has been demonstrated to be induced by genotoxic stress, and is capable of stimulating cell cycle arrest and apoptosis (Barone et al., 1994; Zhan et al., 1994; Zinszner et al., 1998) . Both, MMHFos and MMH-FosRas cells, showed three-and twofold enhanced steady-state mRNA levels of CHOP after conditional c-Fos activation, respectively (Figure 5c ). Moreover, this increase of CHOP was further associated with elevated levels of DOC-1, a downstream target of CHOP, in MMH-FosRas cells. In summary, these data indicate that continuous c-Fos expression causes an enhanced production of ROS, and suggest that the elevated levels of ROS are involved in mediating c-Fos effects.
Bcl-X L prevents the c-Fos-mediated phenotype
In a further set of experiments, we aimed at analysing the impact of antiapoptotic activities provided by members of the Bcl-2 family in c-Fos hepatocytes. Such effectors are of particular interest since they represent potential candidates to neutralize the c-Fos-mediated phenotype in hepatocytes. For this purpose, we generated cell types stably expressing either Bcl-2 or Bcl-X L in combination with hormone-inducible c-Fos. These cell lines, termed MMH-FosBcl-2 and MMH-FosBcl-X L , constitutively overexpressed considerable amounts of exogenous Bcl-2 and Bcl-X L proteins, independent of E2-induced c-Fos activation (Figure 6a ). Western blot analysis further revealed that MMH-Fos, MMH-FosRas and MMH-FosBcl-X L cells were devoid of endogenous Bcl-2 expression. In contrast, all cell types under investigation endogenously expressed Bcl-X L , and MMH-FosBcl-X L cells displayed a Bthreefold overexpression of Bcl-X L . However, MMH-Fos cells showed a strongly reduced Bcl-X L expression after E2-treatment. As found in parental MMH-D3 cells, MMHFosRas and MMH-Bcl-2 exhibited a hormone-independent expression of Bcl-X L . Importantly, the expression of Bcl-2 showed no influence on c-Fos-mediated effects, whereas MMH-FosBcl-X L cells treated with E2 failed to undergo morphological changes (Figure 6b ). Moreover, MMH-FosBcl-X L cells displayed a significant reduction of cell death after induction with E2, which could not be observed in MMH-FosBcl-2 cells (Figure 6c ). Yet, neither Bcl-2 nor Bcl-X L was able to antagonize the cFos-mediated defects in cell cycle progression, since treatment of MMH-FosBcl-2 as well as MMH-Bcl-X L cells with E2 resulted in a significant reduction of DNA synthesis, as observed in MMH-Fos cells (Figure 6d ). In conclusion, these data indicate that c-Fos negatively interferes with Bcl-X L expression. Overexpression of this antiapoptotic protein is able to counteract c-Fosmediated effects of morphological alterations and cell death; however, it fails to neutralize c-Fos-induced cell cycle defects.
Suppression of Ras-mediated malignancy by c-Fos in vitro and in vivo
The consequences of continuous c-Fos expression on its own and the enhancement of c-Fos effects by Ras via MAPK signalling suggest a tumour-suppressive role of Fos in Ras-driven hepatocellular tumorigenesis. To test this hypothesis, we first analysed the ability of various cell types to grow in an anchorage-independent manner in soft agar. As reported recently, MMH-R cells transformed by oncogenic Ha-Ras formed a high number of colonies (Figure 7a ; Gotzmann et al., 2002) . In contrast, MMH-FosRas cells induced by E2 formed a strongly reduced number of colonies that were consistently smaller in size. Even untreated MMHFosRas cells already generated a lower number of colonies most probably due to a basal activity of the cFosER fusion protein. The number of colonies formed by E2-induced MMH-FosRas was reduced to a level observed of either hormone activated or untreated MMH-Fos and parental MMH-D3 cells (Figure 7a ). These data suggest that c-Fos on its own is nontumorigenic and moreover, suppresses the tumorigenicity of malignant hepatocytes in vitro.
These results obtained in vitro could be confirmed in vivo. After subcutaneous injection of MMH-R cells into immunocompromised recipient SCID mice, these malignant cells formed severe tumours that were palpable after 3 days and developed to a high tumour weight after 20 days (Figure 7b ). This tumour formation, however, was significantly attenuated by coexpression of c-Fos, since MMH-FosRas cells induced by E2 in culture established tumours which (i) developed slower in the first week after injection than MMH-R-derived tumours, and (ii) showed a reduction in weight of about 50% after 20 days ( Figure 7b ). As expected, control MMH-Fos cells either induced with E2 or untreated were not able to form tumours. This retardation in tumour development was further examined in immunohistochemical analysis by staining of tumour sections with PCNA, a marker monitoring the cells in the S phase of the cell cycle. This analysis revealed a higher proportion of cycling cells in MMH-R tumours as compared to the ones derived from MMH-FosRas cells (Figure 7c, upper panel) . Further studies on cell death in vivo employing TUNEL assays on histological sections revealed no significant changes in the respective tumours (Figure 7c) , and only particularly selected areas showed a moderate increase of DNA fragmentation in tumours repressed by activated c-Fos. Taken as a whole, these data obtained in vitro and in vivo indicate that c-Fos is a crucial player in hepatocellular tumorigenesis that negatively interferes with malignancy via its inhibitory function in cell proliferation.
Discussion
We employed a hepatocellular tumour model correlating with the establishment of an invasive and metastatic phenotype, and found the transient upregulation and subsequent loss of c-Fos expression during the transition In line with these observations, c-Fos was found to negatively interfere with hepatocellular tumorigenesis driven by oncogenic Ras. Hence, this functional analyses clearly indicate that c-Fos represents a negative regulator of hepatocellular malignancy that is underlined by the tumour-suppressive action in neoplastic hepatocytes.
In this study, we show that the continuous expression of c-Fos can repress cell cycle progression and stimulate cell death of hepatocytes. Using a chimeric c-FosER construct for conditional c-Fos expression, the data described have been raised by activating the c-Fos fusion protein with estradiol. Since the chimeric c-FosER can also be induced with the E2 antagonist 4-hydroxytamoxifen (Reichmann et al., 1992) , comparable but somewhat weaker effects of c-FosER could be detected with the antihormone in hepatocytes (data not shown). As presented, cell cycle inhibition and induction of cell death are accompanied by changes in epithelial cell plasticity, that is, the adoption of a depolarized phenotype. This c-Fos-dependent morphological transition was found to be irreversible, since the shutdown of c-Fos levels by removal of E2 showed no reversion to an epithelial phenotype due to cell death (data not shown). In agreement with these alterations in epithelial morphology, we found that the cell attachment to the substratum was significantly impaired in c-Fos-expressing hepatocytes and was even more lowered in collaboration with active Ha-Ras, as suggested by their altered expression pattern of integrins (M Mikula and W Mikulits, unpublished data). However, the unaffected localization of E-cadherin to cell boundaries after c-Fos activation indicates an intact E-cadherin-mediated cellcell adhesion. This observation is of particular interest since the cytoplasmic domain of E-cadherin has been described to be rapidly released from the cell membrane after cleavage in apoptotic epithelial cells (Steinhusen et al., 2001) . Similarly, another group reported that the cytoplasmic O-glycosylation of E-cadherin blocks the transport of E-cadherin to the cell surface in epithelial cells that are induced to apoptosis (Zhu et al., 2001) . From these data on E-cadherin, we conclude that c-Fos actively modulates epithelial plasticity of hepatocytes, and that these morphological changes are not effects due to the execution of cell death. In accordance with these results, sustained expression of c-FosER after E2-induction has been previously shown to trigger morphogenesis of murine mammary epithelial cells, and even irreversibly induces EMT by establishing an invasive, spindle-shaped phenotype (Reichmann et al., 1992) . Contrary to the data raised in hepatocytes, c-Fos expression conditionally activated by E2 induces EMT in mammary epithelial cells without altering cell proliferation. Furthermore, c-Fos downregulates Ecadherin, which in turn favours cell proliferation through nuclear translocation and transcriptional activation of b-catenin/LEF (Eger et al., 2000; Stockinger et al., 2001) . Similar findings on cell shape alterations and invasiveness induced by c-Fos have been obtained in mammary adenocarcinoma cells (Kustikova et al., 1998) , showing that the expression of genes associated with tumour progression (like members of the urokinase system such as uPA and uPAR) was highly upregulated (Andersen et al., 2002) . From this point of view, it is evident that epithelial cells derived from various tissues share the potential of c-Fos in reprogramming the epithelial phenotype, however, the physiological consequences might be strongly different and depend on the type of tissue.
One of these consequences is apparent by the c-Fosinduced block in the cell cycle progression of hepatocytes. Analysis of the TGF-b pathway in our cell system showed a cytoplasmic localization of Smad2, Smad3 and Smad4, which excludes the fact that TGF-b signalling might be a key regulatory loop in the negative control of the hepatocyte cell cycle ten Dijke et al., 2000; Rossmanith and Schulte-Hermann, 2001) . A more detailed analysis to unravel the molecular mechanisms responsible for these alterations in cell cycle distribution raised the question on the expression of various cell cycle inhibitors. Indeed, conditional activation of c-Fos resulted in a considerable fluctuation of cell cycle regulators at the protein level: whereas p16 INK4A and p57 KIP2 were found to be significantly increased, the abundance of p21 WAF1 and p27 KIP1 proteins declined to lower levels (M Mikula and W Mikulits, unpublished data). Although these data allow no conclusive interpretation on their degradation or sequestration on cyclin-CDK complexes, numerous studies indicate that the cell cycle inhibitors p16 INK4A and p57 KIP2 play a pivotal role in the progression of HCCs (Buendia, 2000) . Whereas the alterations of p21 WAF1 and p27 KIP1 expression levels are controversially reported in the regenerating liver and in HCCs (Albrecht et al., 1998; Qin and Ng, 2001) , the loss of p16 INK4A and p57 KIP2 is clearly correlated with accelerated proliferation of tumours (Nakai et al., 2002) . By interpreting these data, the c-Fos-mediated increase of p16 INK4A and p57 KIP2 might be critical in executing growth inhibition of hepatocytes.
A prospective clue to explain c-Fos-mediated effects is given by the upregulation of the transcription factor CHOP (GADD 153) and its downstream target DOC-1. In particular, CHOP induction has been reported in response to oxidative stress (Guyton et al., 1996) , and in line with our results, the intracellular ROS production that is induced by continuous c-Fos expression in c-Fos suppresses malignant transformation of hepatocytes M Mikula et al hepatocytes is suggested to account for this activation. It is noteworthy that the DOC-1 gene contains a CHOPbinding element in its promoter, and has been recently identified to encode the carbonic anhydrase VI that regulates the pH by catalysing the hydration of metabolically generated CO 2 and increases the proton concentration Sok et al., 1999) . Although an upregulation of DOC-1 was only detected in E2-induced MMH-FosRas cells, an increase of the proton concentration has been observed by the acidification of cell culture supernatants of E2-treated MMH-Fos and MMH-FosRas cells (data not shown). This decrease in pH could be a stimulator of the membrane pore forming activity of the proapoptotic regulator Bax (Antonsson et al., 1997) . Hence, we are tempted to speculate that CHOP represents not only a sensor of c-Fos-mediated ROS production, but may also be involved in the negative regulation of hepatocyte proliferation.
Antiapoptotic activities provided by a distinct subset of Bcl-2 family members antagonize Bax operations, and thus are able to protect from active cell death (Antonsson et al., 1997) . Importantly, coexpression of the apoptosis-protecting factor Bcl-X L was found to prevent the c-Fos-mediated phenotype, whereas Bcl-2 was not sufficient to achieve this rescue. Since endogenous Bcl-2 has not been detected in our hepatic cell model, this prosurvival activity might have no impact on c-Fos-mediated cell death. Consistently, several studies dealing with primary human HCCs reported that Bcl-2 expression is absent in cancerous hepatocytes, and might therefore not be involved in the malignant progression of HCCs (Nakopoulou et al., 1999; Ravazoula et al., 2002) . However, we observed that continuous c-Fos expression on its own led to the downregulation of Bcl-X L . This finding is of particular interest since recent studies showed that enhanced ROS levels are responsible for the decrease of Bcl-X L and subsequent execution of active cell death (Herrera et al., 2001a, b) . These data strongly support the idea that sustained cFos expression negatively interferes with Bcl-X L expression via ROS, and thus, Bcl-X L can be considered as an indirect target of c-Fos in hepatocytes. Along these lines, Bcl-X L expressed in human HCC cells has been described to block apoptosis induced by various cellular stresses (Takehara et al., 2001) , and low levels of Bcl-X L in HCCs correlate with a more favourable prognosis and improved survival of HCC patients (Garcia et al., 2002) .
Studies on TGF-b-mediated apoptosis in primary rat hepatocytes showed that the TGF-b-induced production of ROS diminishes the expression of Bcl-X L , which results in mitochondrial membrane permeabilization followed by cytochrome c release and caspase 3 activation (Herrera et al., 2001a) . Interestingly, this ROS production could be abolished by cycloheximide, indicating that the synthesis of an unknown polypeptide is crucially involved upstream of the generation of oxidative stress. By taking into account the fact that c-Fos is a direct target of TGF-b signalling (Massague, 2000) , whose expression is accompanied by the elevated production of ROS, our data suggest that c-Fos might play a critical role at a very early stage of TGF-bmediated apoptosis of hepatocytes. Taking these aspects into account, it is conceivable that c-Fos mediates cell death of hepatocytes via a similar route as induced by TGF-b signalling.
The phenotype correlating with continuous c-Fos expression in hepatocytes results from a transcriptionally active AP-1 complex, and enhanced effects of c-Fos are caused by the cooperation with MAPK signalling. In contrast to the downregulation of Bcl-X L in MMH-Fos cells after E2 induction, we observed that c-Fos activation in combination with constitutive Ras or exogenous Bcl-2 expression failed to decrease Bcl-X L levels. Several studies reported that Ras/MAPK signalling as well as Bcl-2 action harbours the potential to counteract the decrease of Bcl-X L . These antagonizing functions can be either accomplished by MAPK signalling mediating modulation of regulators such as, for example, Stat or Ets that transcriptionally activate Bcl-X L (Grad et al., 2000; Sevilla et al., 2001) , or by quenching elevated ROS levels via Bcl-2 (Papadopoulos et al., 1998; Lee et al., 2001) . However, the unaltered levels of Bcl-X L in MMHFosRas after E2 induction are not consistent with the strong induction of cell death in these cells, and therefore, the level of endogenous Bcl-X L appears insufficient to antagonize c-Fos-mediated cell death. These data indicate that c-Fos in cooperation with Ras/ MAPK signalling recruits an additional or alternative pathway that is of paramount importance for increasing hepatocyte cell death.
The expression of Ras and c-Fos has been reported to be under tight control and are strictly separated in a time-dependent manner during liver regeneration. As described previously in vivo, c-Fos/AP-1 activity is transiently upregulated early at B1 h after PH, whereas activation of Ras peaks delayed post-PH (Columbano and Shinozuka, 1996; Taub, 1996) . From these patterns, AP-1 activity has been suggested to 'prime' hepatocytes in a prereplicative phase towards an adequate proliferative response, and the subsequent activation of Ras is required for the regulated cell cycle progression during liver regeneration (Taub, 1996; Michalopoulos and DeFrances, 1997; Fausto, 2000) . In this regard, it is important to note that the activation of these individual proteins is mutually exclusive to avoid a fateful imbalance: cell cycle inhibition as well as induction of cell death that would dramatically dampen or even disrupt the proliferation of hepatocytes during liver repopulation.
Taken as a whole, the continuous expression of c-Fos is indicated to act tumour suppressive in hepatocytes that is provided by both, its negative interference with cell cycle progression and its promoting role in cell death. Since various cell types show a proapoptotic function of c-Fos (Smeyne et al., 1993; Marti et al., 1994; Hu et al., 1996; Preston et al., 1996; Hafezi et al., 1997; Mils et al., 1997; Buttyan et al., 1988) , the AP-1 activity containing this critical factor could therefore have broad clinical relevance. In this light, the role of c-Fos appears to be of apparent significance in malignant hepatocytes that exhibit activation of Ras, either through mutations in this central effector protein itself or through the constitutive induction due to the hyperstimulation of receptor tyrosine kinases. In this context, the hepatocellular EMT might be a representative tumour model based on both Ras activation and the promoting role of TGF-b signalling (Gotzmann et al., 2002) . Since the process of EMT correlates with latestage carcinogenesis, it is most notable that c-Fos is transiently upregulated and ceases thereafter to undetectable levels. This aspect tempts us to speculate that the temporary activation of c-Fos is necessary for 'priming' hepatocytes towards the adoption of a migratory and infiltrative phenotype that leads to local tissue invasion and metastasis. Thus, c-Fos is suggested to be an immediate early molecular trigger mediating the progression of TGF-b-secreting liver tumours that are frequently observed in humans (Ito et al., 1991; Bedossa et al., 1995; Factor et al., 1997) . After 'priming' carcinomas to late-stage progression, however, the proto-oncoprotein c-Fos must be inevitably turned off to avoid antagonizing functions in proliferation. Taking these aspects into consideration, c-Fos might represent a versatile therapeutic target in HCCs that could execute its tumour-suppressive functions through a constitutively elevated expression level at advanced tumour stages.
Materials and methods
Cell culture
Immortalized Met murine hepatocytes (MMH-D3, Amicone et al., 1997; Spagnoli et al., 1998) were grown in RPMI 1640 plus 10% foetal calf serum (FCS), 40 ng/ml recombinant human TGF-a (Sigma, St Louis, USA), 30 ng/ml recombinant human insulin-like growth factor II (IGF-I, Sigma, St Louis, USA), 1.4 nm insulin (Sigma, St Louis, USA) and antibiotics as described previously. MMH-R cells expressing oncogenic vHa-Ras and GFP were cultured as outlined recently (Gotzmann et al., 2002) . MMH-Fos and MMH-FosRas cells were generated by stable retroviral transmission of MMH-D3 and MMH-R cells with a vector harbouring the murine c-Fos cDNA fused to the hormone-binding domain of the estrogen receptor (ER, Reichmann et al., 1992) . MMH-FosC40, MMHFosS35, MMH-FosBcl-2 and MMH-Bcl-X L cells resulted from stable retroviral transmission with S35-V12-Ras and C40-V12-Ras (Rodriguez-Viciana et al., 1997), Bcl-2 (Janda et al., 2002) and Bcl-X L (Kieslinger et al., 2000) , respectively. These cell lines were propagated in RPMI 1640, 4% FCS and growth factors as described for MMH-D3. All cells were kept at 371C and 5% CO 2 and routinely screened for the absence of mycoplasma. Conditional activation of cFosER was obtained by adding 1 mm estradiol (E2, Sigma, St Louis, USA) to the culture medium. The low molecular weight compounds PD184.352 (Sebolt-Leopold et al., 1999; a kind gift from Boehringer Ingelheim Pharma KG, Biberach/ Riss, Germany) and LY294.002 (Alexis Corporation, San Diego, USA) were added to the culture medium at concentrations of 5 and 20 mm, respectively. Scavenging of ROS was performed by treating cells with 10 mm NAC (Sigma, St Louis, USA).
Reverse transcription polymerase chain reaction (RT-PCR)
Poly(A) þ mRNA extraction, first-strand cDNA synthesis and PCR were performed as described recently (Gotzmann et al., 2002) . Specific amplification reactions were obtained with the following forward and reverse primers: c-Fos, 5 0 -GCTGACA-GATACACTCCAA-GCGG-3 0 and 5 0 -AGGAAGACGTGT-AAGTAGTGCAG-3 0 ; CHOP, 5 0 -GCAGTCATGG-CAGCT-GAGTCCCT-3 0 and 5 0 -GAGGTGATGCCCACTGTTCA= TGC-3 0 ; DOC-1, 5 0 -AGTGCTGGGCTTAGTTTAGAGCT-TTCC-3 0 and 5 0 -AGATCGATCGATACTGTGTG-TCCGT-TG-3 0 ; BIP, 5 0 -GAAAGGATGGTTAATGATGCTGAG-3 0 and 5 0 -GTCTTC-AATGTCCGCATCCTG-3 0 ; RhoA, 5 0 -GT-GGAATTCGCCTTGCATCTGAGAAGT-3 0 and 5 0 -CACG-AATTCAATTAACCGCATGAGGCT-3 0 . PCR products were analysed by electrophoresis on 1.5% agarose gels after staining with ethidium bromide.
Transient transfections and reporter gene assays
One day before transfection, MMH-Fos or MMH-FosRas cells were plated at a density of 1 Â 10 5 cells per six-well plate. Transient transfections were performed with Lipofectamine Plus as recommended by the manufacturer (Invitrogen, Carlsbad, USA). A control b-galactosidase reporter (0.25 mg) (Eger et al., 2000) was cotransfected with 1 mg of a luciferase reporter construct containing three TPA-responsive elements (termed p3TP-Lux; Wrana et al., 1992) . b-galactosidase and the luciferase reporter were also cotransfected with 1 mg of an expression vector harbouring the dn c-Jun (A63/73, Smeal et al., 1991) . To detect Smad-mediated transactivation of the luciferase reporter, cells were either transfected with ARE plus FAST-1 (Smad2, Germain et al., 2000) or (CAGA)-12-Luc (Smad3, Dennler et al., 1998) , in combination with the b-galactosidase reporter construct. Cells were lysed 48 h after transfection, and the activity of luciferase was determined by a Luminoskan (Labsystems, Farnborough, UK) as described previously (Eger et al., 2000) . All assays were performed in triplicate and results represent the averages of three independent experiments after normalization to b-galactosidase activities.
Western blot analysis
The preparation of cellular extracts, separation of proteins by SDS-polyacrylamide gel electrophoresis and immunoblotting were carried out essentially as described recently (Gotzmann et al., 2002) . The protein extract from 1 Â 10 5 cells per sample was loaded onto gels and immunological detection of proteins was performed with the SuperSignal detection system (Pierce Chemical Company, Rockford, USA). The following primary antibodies were used: anti-Ras (DAKO, Carpinteria, USA), 1 : 250; anti-Bcl-2 (Santa Cruz, CA, USA), 1 : 1000; anti-Bcl-X L (Santa Cruz, CA, USA), 1 : 1000; antiActin (Sigma, St Louis, USA), 1 : 1000. Secondary antibodies (Calbiochem, LaJolla, USA) were used at dilutions of 1 : 10 000.
Confocal immunofluorescence microscopy
Cells grown on filters (Falcon 353090, Becton Dickinson, Franklin Lakes, USA) were fixed and permeabilized as described recently (Gotzmann et al., 2002) . Primary antibodies were used at following dilutions: anti-E-cadherin (Transduction Laboratories, Lexington, UK), 1 : 100; anti-ZO-1 (Zymed Laboratories, South San Francisco, USA), 1 : 75; anti-Smad2 (Transduction Laboratories, Lexington, UK), 1 : 250. After application of cye-dye-conjugated secondary antibodies c-Fos suppresses malignant transformation of hepatocytes M Mikula et al (Jackson Laboratories, West-Grove, USA), imaging of cells was performed with a TCS-SP confocal microscope (Leica, Heidelberg, Germany).
Thymidine incorporation assay and FACS analysis
Cells cultured in the absence or presence of 1 mm E2 were seeded in triplicates in 96-well plates at a density of 1 Â 10 4 cells per well. To monitor DNA synthesis rates of cell populations, cells were incubated with the respective standard medium and pulsed with 1 mCi [ 3 H]thymidine (ICN, Irvine, USA) for 2 h. Subsequently, cells were harvested on glass-fibre filters (Packard, Meriden, USA) and the radioactivity associated with DNA was determined in a microplate scintillation counter (Packard, Meriden, USA). All values depicted correspond to counts (cpm) representing the mean of triplicate measurements. Determination of the cellular DNA content was performed with a flow cytometer (FACSCalibur, Becton Dickinson, Franklin Lakes, USA) after staining DNA with propidium iodide (Gotzmann et al., 2002) .
Clonogenic survival assays
To analyse the clonogenic growth behaviour of cell populations on tissue culture plastic, 500 cells were seeded in a sixwell plate and either uninduced or induced with 1 mm E2 for 48 h, incubated with standard medium for 14 days at 371C in a humidified incubator. Colonies were fixed with methanol/ acetic acid (3 : 1), and stained with 0.25% crystal violet.
Analysis of cell viability
Cells were washed with phosphate-buffered saline (PBS) and fresh medium supplemented with 10% methyl-thiazol tetrazolium (MTT; Sigma, St Louis, USA) was added for 2 h. After removal of the medium, 100 ml of DMSO was added to each well to solubilize the coloured formazan product of MTT reduction in viable cells (Carmichael et al., 1987) . Absorbance was read at 562 nm in a scanning microtitre spectrophotometer plate reader (Anthos Labtec Instruments, Salzburg, Austria). Cell death was analysed by measuring LDH release using the CytoTox 96
s Non-Radioactive Cytotoxicity Assay (Promega, Madison, USA), according to the manufacturer's recommendations. To detect DNA fragmentation (Grasl-Kraupp et al., 1995) , cells were subjected to TUNEL assay using an in situ detection kit (Roche, Mannheim Germany). Fluoresceinlabelled cells were counterstained with propidium iodide (1 mg/ml) and visualized by conventional fluorescence microscopy (Nikon Corporation, Tokyo, Japan).
Determination of ROS production
Cells cultured in the absence or presence of E2 were detached from tissue culture dishes by trypsinization and incubated with the oxidation-sensitive probe DCFH-DA (25 mm; Sigma, St Louis, USA) for 30 min at room temperature (Herrera et al., 2001a) . Subsequently, cells were processed for flow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, USA) to detect the production of ROS. Fluorescent events (2 Â 10 4 ) were monitored at each cytometrical measurement.
In vitro transformation assay
To analyse anchorage-independent growth of cells in soft agar, 5 Â 10 3 cells of each cell type were seeded in triplicate in sixwell plates by mixing with 1.4 ml of 0.3 % agar noble in RPMI 1640 plus 10% FCS. This suspension was layered onto the bottom agar containing 1.4 ml of 0.7% agar noble in RPMI plus 10% FCS and growth factors at a twofold concentration (80 ng/ml TGF-a, 60 ng/ml IGF-II and 2.8 nm insulin) in the presence or absence of 2 mm E2. Colonies were scored and statistically evaluated after 14 days. The assay was performed twice for each cell type.
Tumour formation in vivo
Cells of the particular cell type were detached from the tissue culture plate, washed with PBS, and resuspended in Ringer solution. Subsequently, 2 Â 10 6 cells in 200 ml Ringer solution were subcutaneously injected into immunodeficient SCID/ BALB/c-recipient mice. Each cell type was injected into three individual mice. Tumour formation was viewed periodically by palpation and the tumour weight (mg) was determined essentially as described recently (Gotzmann et al., 2002) . All experiments were performed twice and carried out according to the Austrian guidelines for animal care and protection.
Immunohistochemistry and TUNEL analysis of experimental tumours SCID mice were killed and the obtained tumours were removed and fixed in 4% phosphate-buffered formaldehyde overnight at 41C (Mikula et al., 2001) . For immunohistochemical analysis, paraffin-embedded sections were treated with citric acid buffer (0.01 m, pH 6.0) before staining with a monoclonal antibody against PCNA (1 : 100; Dako, Carpinteria, USA). To detect DNA fragmentation in tumour tissues, an in situ detection kit (Roche, Mannheim, Germany) was employed. After incubation of deparaffinized sections with proteinase K (20 mg/ml) for 15 min at 371C in the presence of fluorescein-labelled dUTP and counterstaining with propidium iodide (1 mg/ml), conventional fluorescence microscopy (Nikon Corporation, Tokyo, Japan) was performed.
